SVCM
CADL icon

Saturn V Capital Management’s Candel Therapeutics CADL Stock Holding History

Saturn V Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34M Buy
3,303,686
+407,098
+14% +$3.08M 4.88% 10
2026
Q1 		$14.2M Buy
+2,896,588
New +$15.8M 2.57% 15

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

Saturn V Capital Management's CADL Position: Q2 2026 in Review

Saturn V Capital Management increased its Candel Therapeutics (CADL) stake by 14% in Q2 2026, buying an estimated $3.08M and bringing the position to 3,303,686 shares worth $34M. The position accounts for 4.88% of the portfolio, ranked #10.

Saturn V Capital Management first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Saturn V Capital Management held 3,303,686 shares of Candel Therapeutics worth $34M as of Q2 2026.
  • Saturn V Capital Management bought 407,098 Candel Therapeutics shares in Q2 2026, an estimated $3.08M.
  • Candel Therapeutics made up 4.88% of Saturn V Capital Management's portfolio in Q2 2026, its #10 holding.
  • Saturn V Capital Management first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.